| Similar Articles |
|---|
 |
The Motley Fool
April 23, 2007
Brian Lawler |
Trimeris Isn't Tumbling Trimeris announces first-quarter sales numbers for its HIV drug Fuzeon. Shares of the company were up 25% last week after it reported stronger-than-expected sales of the fusion inhibitor.   |
The Motley Fool
November 20, 2006
Karl Thiel |
Trimeris Begs for a Buyout The pharmaceutical's reorganization plan practically posts a "for sale" sign. So will Roche -- or someone else -- bite? Investors, take note. |
The Motley Fool
November 30, 2007
Brian Lawler |
Not What Trimeris Needs Small biopharma Trimeris revealed that it and partner Roche were being sued for patent infringement by Novartis over Trimeris' only marketed compound, Fuzeon. |
The Motley Fool
April 23, 2004
Charly Travers |
A Difficult Drug Launch Investors expected a lot from Fuzeon, Trimeris' HIV drug therapy. However, anticipated sales for the biotechnology company didn't materialize. |
The Motley Fool
January 30, 2008
Brian Lawler |
The Competition Bites Trimeris Rivals lead to lower sales of the small specialty pharmaceutical's only marketed drug. |
The Motley Fool
March 19, 2007
Brian Lawler |
Trimeris Gets Trimmed Shares of the drug developer are down after a management shakeup. With shares trading near their 52-week lows amid all the pessimism, now is a good time for less-risk adverse investors to buy in. |
The Motley Fool
August 15, 2007
Brian Lawler |
Call for Change at Trimeris A shareholder group criticizes tiny Trimeris about its spending on research. In an SEC filing, HealthCor, which owns 15% of the outstanding shares, called for the pharmaceutical company to cut back on its research and development expenses and to explore selling the company. |
The Motley Fool
July 13, 2004
Charly Travers |
With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market. |
The Motley Fool
November 16, 2007
Brian Lawler |
Trimeris Gets a Cleanup Hitter Tiny drug developer Trimeris announces that it has finally found a permanent CEO to help get itself in order following the resignation of its former leader a year ago. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
August 27, 2010
Brian Orelli |
Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen. |
Chemistry World
August 4, 2008
Pete Mitchell |
Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate. |
The Motley Fool
June 21, 2007
Brian Lawler |
Pfizer Gets Held Up The FDA issues an approvable letter for its novel HIV compound. Investors, take note. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
May 2, 2007
Brian Lawler |
Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note. |
The Motley Fool
January 31, 2008
Brian Lawler |
Don't Forget Roche Roche, the largest biopharma, by market capitalization, had a terrific 2007. Since it is not publicly listed on the major U.S. stock exchanges, the company never gets its fair share of attention. |
The Motley Fool
January 7, 2004
Alyce Lomax |
Try Again, Trimeris Headline skimmers, beware. When a company plays "hide and seek," and the object that's hiding is a piece of bad news, it's no laughing matter to investors. Trimeris got busted Monday following market close after it issued what was considered a rather deceptive press release. |
The Motley Fool
October 17, 2006
Brian Lawler |
Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at. |
The Motley Fool
June 26, 2008
Brian Lawler |
Ardea Takes the More Exciting Route Ardea Bioscicences announces phase 2a data for its lead anti-HIV drug that is good enough to encourage further testing. |
The Motley Fool
June 7, 2011
Brian Orelli |
Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal. |
The Motley Fool
May 28, 2010
Brian Orelli |
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree. |
BusinessWeek
November 24, 2003
John Carey |
Barring The Door Against AIDS A new generation of drugs focuses on keeping the virus from entering cells. |
The Motley Fool
July 21, 2008
Brian Lawler |
Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own. |
BusinessWeek
November 25, 2009
Arlene Weintraub |
Can Roche Leave Genentech Alone? Now that Roche has acquired the biotech superstar, success will depend on keeping some distance. |
Managed Care
May 2005 |
Antiretroviral Coverage Lacking in 30 Percent of ADAPs There are 57 AIDS Drug Assistance Programs (ADAPs), yet nearly 30% do not include coverage of all FDA-approved antiretroviral therapies on their formularies, and South Dakota does not provide any protease inhibitor coverage at all, according to an annual report. |
The Motley Fool
June 30, 2011
Brian Orelli |
2 Backdoor Biotech IPOs to Watch Just don't buy yet. |
Pharmaceutical Executive
October 1, 2005
Mark J. Ahn |
It's All Academic: Biotechs Looking to Universities Pharmaceuticals and academic institutions are forming alliances at an increasing rate to exploit the promise of emerging biological insights. |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead. |
BusinessWeek
October 1, 2007
Conrad Wilson |
A Dream Team Of Drugs And Diagnosis? If a deal is struck, a Roche-Ventana team could help launch a medical revolution. |
BusinessWeek
July 1, 2010
Doherty & Waters |
Post-Buyout, Genentech's DNA Is Dominant Bought out for $47 billion, the biotech pioneer has gained the upper hand |
The Motley Fool
August 14, 2008
Brian Lawler |
Genentech Asks Roche to Pay Up In one of the more friendly spurnings of a buyout offer in recent months, Genentech calls Roche's $89-per-share buyout offer too low, and very nicely implies that Roche should up its bid. |
